Amedisys (AMED) Down 0.8% Since Last Earnings Report: Can It Rebound?

23.05.25 17:30 Uhr

Werte in diesem Artikel
Aktien

81,50 EUR 0,50 EUR 0,62%

Indizes

18.737,2 PKT -188,5 PKT -1,00%

A month has gone by since the last earnings report for Amedisys (AMED). Shares have lost about 0.8% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Amedisys due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, estimates review have trended downward during the past month.VGM ScoresAt this time, Amedisys has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of this revision has been net zero. Notably, Amedisys has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.0% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amedisys, Inc. (AMED): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Amedisys und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Amedisys

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Amedisys

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Amedisys Inc.

Wer­bung

Analysen zu Amedisys Inc.

DatumRatingAnalyst
14.12.2018Amedisys Equal WeightBarclays Capital
30.10.2018Amedisys BuyThe Benchmark Company
19.03.2018Amedisys OutperformRBC Capital Markets
09.11.2017Amedisys HoldThe Benchmark Company
09.11.2017Amedisys Sector PerformRBC Capital Markets
DatumRatingAnalyst
30.10.2018Amedisys BuyThe Benchmark Company
19.03.2018Amedisys OutperformRBC Capital Markets
08.11.2017Amedisys BuyMizuho
02.11.2017Amedisys BuyThe Benchmark Company
03.05.2017Amedisys BuyMizuho
DatumRatingAnalyst
14.12.2018Amedisys Equal WeightBarclays Capital
09.11.2017Amedisys HoldThe Benchmark Company
09.11.2017Amedisys Sector PerformRBC Capital Markets
03.05.2017Amedisys HoldThe Benchmark Company
01.03.2017Amedisys NeutralMizuho
DatumRatingAnalyst
10.01.2012Amedisys underperformRobert W. Baird & Co. Incorporated

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Amedisys Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen